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Abstract
Introduction:  The  mandibular  advancement  device  (MAD)  is  a  option  to  treat  patients  with
Obstructive  Sleep  Apnea  Syndrome  (OSAS).
Objective:  To  assess  the  inﬂuence  of  upper  airway  abnormalities  on  the  success  of  and  adher-
ence to  MAD  in  patients  with  OSAS.
Methods:  Prospective  study  with  30  patients  with  mild  to  moderate  OSAS  and  indications  for
MAD. The  protocol  included  questionnaires  addressing  sleep  and  nasal  complaints,  polyso-
mnography,  and  upper  airway  assessment.  The  analyzed  parameters  of  patients  who  showed
therapeutic  success  and  failure  and  those  who  exhibited  good  and  poor  treatment  adherence
were compared.
Results:  28  patients  completed  the  protocol;  64.3%  responded  successfully  to  treatment  with
MAD, and  60.7%  exhibited  good  adherence  to  treatment.  Factors  associated  with  greater  success
rates were  younger  age  (p  =  0.02),  smaller  cervical  circumference  (p  =  0.05),  and  lower  AHI  at
baseline (p  =  0.05).  There  was  a  predominance  of  patients  without  nasal  abnormalities  among
patients treated  successfully  compared  to  those  with  treatment  failure  (p  =  0.04),  which  was
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not  observed  in  relation  to  adherence.  Neither  pharyngeal  nor  facial  skeletal  abnormalities
were signiﬁcantly  associated  with  either  therapeutic  success  or  adherence.
Conclusion:  MAD  treatment  success  was  signiﬁcantly  lower  among  patients  with  nasal  abnor-
malities;  however,  treatment  adherence  was  not  inﬂuenced  by  the  presence  of  upper  airway
or facial  skeletal  abnormalities.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
PALAVRAS-CHAVE
Apneia  do  sono  tipo
obstrutiva;
Aparelhos
ortodônticos
removíveis;
Exame  físico;
Nariz
O  impacto  das  alterac¸ões  da  via  aérea  superior  na  adesão  e  sucesso  do  tratamento
com  aparelho  intraoral  na  Síndrome  da  Apneia  Obstrutiva  do  Sono
Resumo
Introduc¸ão:  O  Aparelho  Intraoral  (AIO)  é  uma  opc¸ão para  tratamento  da  Síndrome  da  Apneia
Obstrutiva  do  Sono  (SAOS).
Objetivos:  Avaliar  a  inﬂuência  das  alterac¸ões  da  VAS  e  esqueléticas  faciais  através  de  uma
avaliac¸ão clinica  sistematizada  no  sucesso  e  adesão  ao  (AIO)  em  pacientes  com  (SAOS).
Método: Estudo  prospectivo  em  que  foram  avaliados  30  pacientes  com  SAOS  leve  a  moderada
e indicac¸ão  de  AIO.  Protocolo  incluiu  questionários  de  sono  e  queixas  nasais;  polissonograﬁa  e
avaliac¸ão da  VAS  por  rinoscopia  anterior  e  oroscopia.  Os  parâmetros  analisados  foram  compara-
dos entre  pacientes  com  sucesso  e  insucesso,  e  com  boa  e  má  adesão  à  terapia.
Resultados:  Completaram  o  protocolo  28  pacientes.  O  sucesso  ao  tratamento  foi  de  64,3%  e
a adesão  60,7%.  Os  fatores  associados  ao  sucesso  foram  menor  idade,  menor  circunferên-
cia cervical  e  menor  IAH  basal.  Quanto  à  presenc¸a  de  alterac¸ões  nasais,  houve  predomínio
de pacientes  sem  alterac¸ão  nasal  entre  os  pacientes  com  sucesso  comparados  àqueles  com
insucesso (p  =  0,04);  o  que  não  foi  observado  em  relac¸ão  à  adesão.  Quanto  às  alterac¸ões
faríngeas  e  alterac¸ões  esqueléticas  faciais,  não  houve  signiﬁcância.
Conclusão:  O  sucesso  do  tratamento  com  AIO  foi  signiﬁcativamente  menor  nos  pacientes  com
alterac¸ões nasais,  porém  a  adesão  não  foi  inﬂuenciada  pela  presenc¸a  de  alterac¸ões  de  VAS  ou
esqueléticas  faciais.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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he  treatment  of  choice  for  Obstructive  Sleep  Apnea  Syn-
rome  (OSAS)  is  the  use  of  continuous  positive  airway
ressure  (CPAP),  especially  in  severe  cases.1 In  mild  to  mod-
rate  and  primary  snoring  cases,  other  treatments  can  be
sed,  such  as  the  mandibular  advancement  device  (MAD).1,2
It  is  estimated  that  nasal  obstruction  is  present  in  approx-
mately  64%  of  patients  with  OSAS  and  most  of  these  patients
ave  associated  anatomical  alterations,  such  as  deviated
eptum  and  inferior  turbinate  hypertrophy.3 Although  there
ave  been  studies  demonstrating  the  presence  or  absence
f  an  association  between  nasal  alterations  and  their  treat-
ent  with  CPAP  adherence,3--5 no  studies  have  demonstrated
hether  the  nasal  and  upper  airway  (UA)  alterations  might
r  might  not  interfere  with  successful  treatment  by  or  adher-
nce  to  MAD.
Zeng  et  al.  obtained  data  suggesting  that  increased  nasal
esistance  can  negatively  inﬂuence  MAD  treatment  out-
omes;  it  represents,  to  date,  the  only  study  in  literature
hat  performed  nasal  assessment  through  rhinomanometry
n  patients  with  MAD.6
a
m
I
iThe  scarcity  of  studies  that  have  assessed  the  presence
f  UA  and  facial  skeleton  alterations  using  otorhinolaryngo-
ogical  physical  examination  in  patients  with  OSAS  referred
or  treatment  with  MAD,  and  have  also  evaluated  the  asso-
iation  of  these  alterations  with  treatment  success  and
dherence,  were  the  reasons  that  prompted  this  research.
hus,  this  study  aimed  to  evaluate  the  inﬂuence  of  UA  and
acial  skeletal  alterations  through  a  systematic  and  stan-
ardized  clinical  assessment  of  the  success  and  adherence
o  treatment  of  OSAS  with  MAD.
ethods
ample
 total  of  30  adult  patients  from  the  outpatient  clinic
pecialized  in  treating  sleep-related  disorders  during  2006
nd  2007,  who  had  polysomnography-conﬁrmed  mild  to
oderate  OSAS  according  to  the  diagnostic  criteria  of  the
nternational  Classiﬁcation  of  Sleep  Disorders,  2005,7 with
ndication  for  MAD  were  included  in  this  study.  The  protocol
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OUpper  airway  abnormalities  on  the  success  and  adherence  t
was  submitted  to  the  ethics  and  research  committee,  CEP
No.  0162/06.  Patients  who  agreed  to  participate  signed  the
informed  consent.
Inclusion  criteria  were  patients  aged  25--65  years,  of  both
genders,  with  mild  to  moderate  OSAS,  with  apnea--hypopnea
index  (AHI)  between  5/h  and  30/h.
Exclusion  criteria  included  patients  with  other  sleep  dis-
orders  rather  than  OSAS,  with  previous  clinical  or  surgical
treatments  for  OSAS,  users  of  alcohol,  stimulants,  or  seda-
tives,  those  with  loss  of  posterior  dental  support  that  would
compromise  the  retention  of  MAD,  those  with  active  peri-
odontal  disease,  and  those  with  protrusion  displacement
<6  mm.
Protocol
All  patients  were  submitted  to  an  evaluation  protocol,  which
consisted  of  applying  a  sleepiness  questionnaire  (Epworth
Sleepiness  Scale  [ESS]),8 anthropometric  examination  (neck
circumference  and  body  mass  index  [BMI]),  UA  and  facial
skeletal  examination,  and  overnight  polysomnography  with
MAD.  The  protocol  was  applied  on  the  day  the  MAD  was
provided  and  after  120  days  of  MAD  use.
Patients  also  completed  a  daily  questionnaire  on  MAD  use
and  a  sleep  diary,  which  were  completed  during  all  120  days
of  the  study.
After  the  end  of  the  protocol,  it  was  possible  to  separate
patients  between  groups  with  good  and  poor  compliance,
and  between  groups  with  treatment  success  and  treatment
failure  with  MAD.  The  clinical  data,  polysomnographic  data,
and  upper  airway  and  facial  skeleton  physical  examination
ﬁndings  were  compared  between  the  groups.  The  criteria
used  for  treatment  success  and  adherence  are  described
below.
Tools  used  in  the  study
All  dental  assessment  and  follow-up  of  patients  were
carried  out  by  the  same  dentist,  trained  in  the  area
of  sleep  medicine.  Before  the  study,  all  patients  were
submitted  to  orthodontic  assessment  and  the  maximum
mandibular  advancement  was  measured.  Next,  the  MAD  was
custom-made  for  each  patient,  with  an  initial  mandibular
advancement  of  50%  of  the  maximum  mandibular  advance-
ment.  After  the  start  of  the  protocol,  patients  were
instructed  to  return  weekly  for  the  MAD  to  be  advanced
by  0.5  mm  at  each  visit,  until  they  reached  the  maximum
comfortable  mandibular  advancement.  During  these  return
visits,  patients  brought  the  sleep  and  MAD  use  diaries,  which
will  be  further  detailed  below.  Any  eventual  complications
were  treated.
The  MAD  model  used  in  the  study  was  the  Brazilian
Dental  Appliance  (BRD).  BRD  is  an  adjustable  mandibu-
lar  repositioning  device.  It  has  two  independent  expanding
mechanisms  --  screws  positioned  with  the  long  axis  in  the
anteroposterior  direction.  Two  independent  palate  rods
emerge  from  these  expanding  mechanisms,  one  on  the
right  and  one  on  the  left,  which  are  inserted  inferiorly
into  two  small  tubes  located  in  the  anterior  portion,  dis-
tal  to  the  mandibular  canines,  of  the  lower  acrylic  support
base.  This  proposed  design  allows  successive  advances  in  the
v
p
s
Cndibular  advancement  device  treatment  665
andibular  position,  without  preventing  lateral  mandibular
ovements.  In  other  words,  when  the  device  is  in  place,
ven  when  the  jaw  is  in  a  more  anterior  position,  patients
ay  perform  lateral  movements  and  have  a  small  mouth
pening.9
uestionnaires
he  patients  were  assessed  for  daytime  sleepiness  by  apply-
ng  the  ESS.8 The  scale  was  administered  to  both  groups,
oth  at  the  baseline  and  at  the  end  of  the  assessment.  The
um  of  the  total  score  ranges  from  0  (zero)  to  24,  and  scores
9  suggest  excessive  daytime  sleepiness.
The  sleep  and  MAD-use  dairies  consisted  of  notation
ables,  whose  purpose  was  to  provide  the  necessary  infor-
ation  for  the  study  and  that  contained  the  days  of  the
onth  and  the  week.  In  them,  the  patients  recorded  a  series
f  information  during  the  study  phases,  including  the  time
heir  sleep  started  and  ﬁnished,  when  they  awakened  during
he  night,  and  when  they  put  on  or  removed  the  device.
The  sleep  and  MAD-use  diaries  were  used  to  deﬁne
hether  patients  had  good  or  poor  adherence  to  MAD,  with
he  former  being  those  who  had  used  it  for  more  than  90%
f  the  time  in  the  previous  week.
pper  airway  examination3,10
pper  airway  (UA)  physical  examination  consisted  of  ante-
ior  rhinoscopy,  oroscopy,  and  ﬂexible  ﬁberoptic  nasal
aryngoscopy.  Patients  considered  as  having  nasal  alterations
ere  those  with  septal  deviation  grade  II  (deviation  that
ompresses  the  inferior  nasal  turbinate)  or  III  (deviation  that
ompresses  the  inferior  nasal  turbinate,  touching  the  lateral
all),  or  those  with  grade  I  septal  deviation  (deviation  that
oes  not  touch  the  inferior  nasal  turbinate)  associated  with
requent  nasal  obstruction  complaints  (present  every  day  or
lmost  every  day)  or  complaints  of  frequent  rhinitis  (rhinor-
hea  and/or  sneezing  and/or  pruritus,  every  day  or  almost
very  day),  or  those  with  inferior  turbinate  hypertrophy  on
hysical  examination.
Those  with  pharyngeal  abnormalities  had  three  or  more
f  the  following  alterations:  soft  palate  webbing,  posterior
oft  palate,  thick  soft  palate,  long  uvula,  and  thick  uvula.
The  variables  modiﬁed  Mallampati  classiﬁcation  and  size
f  palatine  tonsils  was  studied  separately,  with  grade  III  and
V  tonsils  (occupying  more  than  50%  of  the  oropharyngeal
pace)  considered  hyperplastic.
In  addition,  patients  with  presence  or  absence  of  facial
keletal  alterations  were  grouped,  considered  as  present
hen  one  or  more  of  the  following  alterations  were
bserved:  retrognathia  at  facial  proﬁle  assessment,  ogival
ard  palate,  or  Angle  class  II  dental  occlusion.
olysomnography  with  MAD
vernight  polysomnography  with  MAD  was  performed  by  pre-
iously  trained  professionals,  after  120  days  of  use.  The
olysomnography  device  used  was  an  EMBLA  computerized
ystem  (EMBLATM S7000;  EMBLA  Systems,  Inc.  --  Broomﬁeld,
O,  United  States).  The  biological  variables  were  measured
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y  electroencephalography  (C3/A2,  C4/A1,  O1/A2,  O2/A1),
ilateral  electro-oculography,  submental  and  tibial  elec-
romyography,  electrocardiography  (modiﬁed  V2),  oral  and
asal  breathing  through  a  thermistor  and  nasal  ﬂow  through
 cannula  with  pressure  transducer,  thoracic  and  abdominal
ovements  by  uncalibrated  inductance  plethysmography,
noring  by  a  microphone,  oxyhemoglobin  saturation  by  pulse
ximetry,  and  body  position  sensor.
Sleep  staging  was  performed  by  a  trained  polysomno-
raphist,  based  on  the  criteria  of  Rechtschataffen  and
ales.11 Respiratory  and  arousal  events,  as  well  as  spo-
adic  lower-limb  movements,  were  analyzed  according  to
riteria  established  by  the  American  Academy  of  Sleep
edicine.12
Polysomnography  was  also  used  to  deﬁne  which  patients
chieved  treatment  success,  as  a  50%  AHI  reduction  and  ≤10
vents/h  deﬁned  this  criterion.
tatistical  analysis
he  Kolmogorov--Smirnov  normality  test  was  applied  for  all
ariables,  which  were  expressed  as  mean  and  standard  devi-
tion,  as  they  showed  normal  distribution.
Student’s  t-test  was  used  for  comparison  between  the
roups  for  independent  samples  and  GLM  (two-way  repeated
easures  ANOVA).  Student’s  t-test  for  dependent  samples
as  used  for  comparisons  before  and  after  treatment  in  all
atients.
The  chi-squared  test  was  used  to  compare  categorical
ariables.  A  logistic  regression  model  was  also  used,  with
reatment  success  and  adherence  used  as  dependent  varia-
les.  The  signiﬁcance  value  was  set  at  0.05  and  the  software
sed  was  Statistic  6.1.
esults
f  the  30  selected  patients,  two  did  not  return  for  the
ssessment  and,  therefore,  28  completed  the  protocol  and
ere  included  in  the  study.  No  patients  stopped  using  the
AD  during  the  protocol.
As  for  the  assessed  descriptive  data,  the  mean  age
f  patients  was  48.8  ±  11.3  years;  nine  (32.1%)  were
ales  and  19  (67.9%)  were  females.  The  mean  BMI  was
7.4  ±  3.8  kg/m2,  and  the  mean  neck  circumference  was
8.3  ±  3.3  cm.
After  all  patients  had  completed  the  baseline  assess-
ent  prior  to  using  MAD  and  had  achieved  the  maximum
omfortable  protrusion  with  MAD,  the  questionnaires  and
olysomnographic  parameters  revealed  some  signiﬁcant  dif-
erences:  decrease  in  the  Epworth  Sleepiness  Scale  (ESS)
f
t
T
Table  1  Comparison  of  clinical  parameters  between  patients  wit
Good  adherence  (n  =  17)  Poor  ad
Age  (years)  47.9  ±  10  50.3  ±  
BMI (kg/m2)  28.5  ±  3  25.7  ±  
NC (cm)  37.1  ±  3  35.1  ±  
BMI, body mass index; NC, neck circumference.
Statistically signiﬁcant p-value <0.05 (Student’s t-test for independentPrescinotto  R  et  al.
core  from  13.4  ±  6.1  to  11.7  ±  6.3  (t26 =  2.47;  p  =  0.02);
eduction  of  AHI  from  17.5  ±  8.8  to  8.8  ±  6.0  (t27 =  6.2,
 < 0.001);  decreased  arousal  index,  from  15.9  ±  6.7  to
0.1  ±  5.1  (t27 =  4.5;  p  <  0.001),  and  decrease  in  the  percent-
ge  of  time  with  oxygen  saturation  <90%,  from  0.71  ±  1.4  to
.07  ±  0.14  (t26 =  2.5,  p  =  0.017).
Of  the  28  patients,  17  (60.7%)  had  good  adherence  to
AD  use,  whereas  11  (39.3%)  showed  poor  adherence.  The
linical  parameters  at  baseline  showed  no  statistically  sig-
iﬁcant  differences  between  the  good  and  poor  adherence
roups  (Table  1).
The  AHI  values  (F  =  4.5;  p  <  0.05)  and  arousal  index
F  =  6.9;  p  <  0.05)  differed  between  the  groups  at  baseline,
nd  were  higher  in  the  poor  adherence  group  (Table  2).
With  use  of  the  MAD  in  both  groups  (both  good  and  poor
dherence)  there  was  a decrease  in  the  ESS  score  (F7.1  =  5.9,
 < 0.05),  AHI  (F  =  41.8;  p  <  0.05),  arousal  index  (F  =  24.4;
 < 0.05),  as  well  as  in  the  percentage  of  desaturation  time
elow  90%  (F  =  8.18;  p  < 0.05;  Table  2).
Of  the  28  patients,  18  (64.3%)  attained  treatment  suc-
ess,  according  to  the  standard  criteria.  When  comparing
he  two  groups  at  baseline  --  successful  and  unsuccess-
ul  treatment  -- the  only  clinical  parameter  that  showed
 statistically  signiﬁcant  difference  was  a younger  age  in
he  treatment  success  group  (44.8  ±  9  vs.  56  ±  10;  t  =  −2.8;
f  =  26;  p  <  0.001;  Table  3).
When  comparing  the  groups  with  treatment  success
nd  failure  at  baseline,  there  were  no  differences  in  the
SS  and  PSG  parameters,  but  after  treatment  with  MAD,
t  was  observed  that  the  patients  in  the  success  group
ad  lower  AHI  values  (F  =  14.2;  p  <  0.01)  and  arousal  index
F  =  7.1;  p  <  0.05),  as  expected  by  the  adopted  success  crite-
ia  (Table  4).
When  patients  in  both  groups  were  assessed  together
treatment  success  and  failure),  after  MAD  use,  there  was
 reduction  in  the  ESS  (F  =  5.9;  p  <  0.05);  AHI  (F  =  28.2,
 < 0.001);  arousal  index  per  hour  of  sleep  (F  =  13.0;
 < 0.01);  and  the  percentage  of  desaturation  time  <90%
F  =  6.0;  p  <  0.05;  Table  4).
When  assessed  individually  or  in  groups,  the  variables
sed  to  form  the  groups  of  patients  with  pharyngeal,  nasal,
nd  craniofacial  alterations  showed  no  signiﬁcant  differ-
nces  in  relation  to  treatment  adherence  (Table  5).  As  for
reatment  success,  it  was  observed  that  the  presence  of
bstructive  septal  defects  (grades  II  or  III;  p  =  0.04)  and  pres-
nce  of  nasal  alterations  (p  =  0.04)  were  more  frequent  in
he  treatment  failure  group  (Table  6);  this  was  not  observed
or  the  pharyngeal  and  craniofacial  variables.
The  logistic  regression  model  was  used  to  identify  fac-
ors  associated  with  treatment  adherence  and  success.
he  following  variables  were  included:  age,  gender,  neck
h  good  and  poor  adherence  to  MAD  at  baseline.
herence  (n  =  11)  t  df  p
12  −0.5  26  0.59
3  1.9  26  0.06
2  1.6  26  0.10
 samples).
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Table  2  Comparison  of  the  Epworth  Sleepiness  Scale  and  polysomnography  parameters  between  patients  with  good  and  poor
adherence to  the  mandibular  advancement  device  (MAD)  at  baseline  and  after  120  days  of  MAD  use.
Good  adherence  (n  =  17)  Poor  adherence  (n  =  11)  p  (group  and
time  interaction)
Basal  With  MAD  Basal  With  MAD
ESS  13.6  ±  6 12.1  ±  6a 12.0  ±  6 9.6  ±  6a 0.74
AHI (events/hour) 14.7  ±  7 7.5  ±  5a 23.2  ±  9b 11.3  ±  6a 0.18
SE (%)  87.2  ±  5  87.6  ±  5  88.3  ±  9  86.0  ±  9  0.15
N3 (%)  18.1  ±  5  17.7  ±  7  18.2  ±  5  21.2  ±  11  0.32
REM (%)  18.9  ±  3  19.3  ±  4  20.0  ±  6  22.3  ±  6  0.66
AI (events/hour)  13.3  ±  6  9.2  ±  4a 20.7  ±  4b 11.6  ±  5a 0.09
SpO2 MIN  (%)  86.3  ±  3  87.4  ±  5  85.2  ±  4  88.4  ±  2  0.34
SpO2 <90%  (%)  0.4  ±  1  0.04  ±  0.1a 1.3  ±  1.9  0.1  ±  0.2a 0.18
ESS, Epworth Sleepiness Scale; AHI, apnea/hypopnea index per hour of sleep; SE, sleep efﬁciency; N3, percentage of slow-wave sleep;
REM, percentage of rapid eye movement sleep; AI: arousal index per hour of sleep, SpO2 MIN: minimum oxyhemoglobin saturation; SpO2
<90%, percentage of desaturation time <90%; NS, non-signiﬁcant statistical value. GLM test for repeated measures (two-way ANOVA).
Statistically signiﬁcant p-value <0.05.
a p < 0.05 (baseline × with MAD).
b p < 0.05 (good adherence × poor adherence at baseline).
Table  3  Comparison  of  clinical  parameters  between  patients  showing  successful  and  unsuccessful  treatment  with  MAD  at
baseline.
Successful  (n  =  18) Unsuccessful  (n  =  10) t  df  p
Age  (years)  44.8  ±  9  56  ±  10  −2.8  26  <0.001
BMI (kg/m2)  27.1  ±  4  28  ±  3  −0.6  26  0.54
NC (cm)  36.3  ±  3  36.4  ±  2  −0.07  26  0.94
dent
(
(BMI, body mass index; NC, neck circumference.
Statistically signiﬁcant p-value <0.05 (Student’s t-test for indepen
circumference,  ESS,  AHI,  arousal  index,  BMI,  pharyngeal
alterations,  nasal  alterations,  and  craniofacial  alterations.
The  ﬁndings  did  not  show  statistically  signiﬁcant  factors
associated  with  adherence;  however,  regarding  treatment
success,  the  younger  the  age  (OR:  0.74  [0.58--0.95];
p  =  0.02),  the  smaller  the  neck  circumference  (OR:  0.48
[0.23--1.00];  p  =  0.05)  and  the  lower  the  baseline  AHI
D
T
w
Table  4  Comparison  of  the  Epworth  Sleepiness  Scale  and  polyso
and unsuccessful  treatment  with  MAD  at  baseline  and  120  days  aft
Successful  (n  =  18)  
Basal  With  MAD  
ESS  13.8  ±  4  11.9  ±  5a
AHI (events/hour)  15.2  ±  8  5.2  ±  2a
SE (%)  89.0  ±  5  89.3  ±  5  
N3 (%)  17.5  ±  6  20.2  ±  8  
REM (%)  19.4  ±  5  20.7  ±  4  
AI (events/hour)  14.7  ±  6  7.7  ±  3a
SpO2 MIN  (%)  86.2  ±  3  88.9  ±  2  
SpO2 <90%  (%)  0.6  ±  1  0.03  ±  0.05a
ESS, Epworth Sleepiness Scale; AHI, apnea/hypopnea index per hour o
REM, percentage of REM sleep; AI, arousal index per hour of sleep; SpO2
of desaturation time <90%; NS, non-signiﬁcant statistical value. GLM te
Statistically signiﬁcant p-value <0.05.
a p < 0.001 (basal × with MAD).
b p < 0.05 (treatment success × failure with MAD). samples).
OR:  0.75  [0.57--1.00];  p  =  0.05),  the  greater  the  success
Table  7).iscussion
he  main  ﬁnding  of  this  study  was  that  successful  treatment
ith  MAD  was  signiﬁcantly  less  likely  in  patients  with  nasal
mnography  parameters  between  patients  showing  successful
er  MAD  use.
Unsuccessful  (n  =  10)  p  (group  and
time  interaction)
Basal  With  MAD
11.8  ±  8  10.0  ±  7a 0.95
22.3  ±  8  15.8  ±  5a,b 0.26
85.0  ±  9  82.8  ±  8  0.34
19.4  ±  4  16.3  ±  10  0.09
19.1  ±  4  19.6  ±  7  0.71
17.9  ±  6  14.5  ±  5a,b 0.22
85.4  ±  3  85.6  ±  6  0.27
0.9  ±  1  0.1  ±  0.2a 0.71
f sleep; SE, sleep efﬁciency; N3, percentage of slow-wave sleep;
MIN, minimum oxyhemoglobin saturation; SpO2 <90%, percentage
st for repeated measures (two-way ANOVA).
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Table  5  Comparison  of  upper  airway  assessment  and  cra-
niofacial  parameters  between  patients  with  good  and  poor
adherence  to  MAD  at  baseline.
Individual  variables  Good
adherence
(n  =  17)
Poor
adherence
(n  =  11)
p
Soft  palate  webbing  11  (64.7%)  9  (81.8%)  0.30
Posterior  soft  palate  6  (35.3%)  5  (45.4%)  0.44
Thick soft  palate  3  (17.6%)  1  (9%)  0.48
Thick uvula  10  (58.8%)  7  (63.6%)  0.56
Long uvula 10  (58.8%) 5  (45.4%) 0.38
Pharyngeal  alteration 9  (52.9%) 6  (54.5%) 0.62
MMI  class  III/IV 16  (94.1%) 10  (90.9%) 0.64
Grade  III/IV  palatine  tonsils  1  (5.9%)  0  (0.0%)  0.60
Class II  dental  occlusion  1  (5.9%)  1  (9%)  0.64
Retrognathia  1  (5.9%)  2  (18.2%)  0.34
Craniofacial  alteration  11  (64.7%)  6  (54.5%)  0.44
Ogival hard  palate  9  (52.9%)  4  (36.4%)  0.32
Frequent  nasal  obstruction  11  (64.7%)  4  (36.4%)  0.14
Frequent  rhinopathy
complaint
10  (58.8%)  5  (45.4%)  0.38
Grade I  septal  deviation  8  (47%)  4  (36.4%)  0.43
Grade II/III  septal  deviation  3  (17.6%)  2  (18.2%)  0.67
Inferior  nasal  turbinate
hypertrophy
10  (58.8%)  4  (36.4%)  0.22
a
a
f
a
a
v
p
t
d
a
e
c
e
o
t
c
a
a
Table  6  Comparison  of  upper  airway  assessment  and  cra-
niofacial  parameters  between  patients  with  successful  and
unsuccessful  treatment  with  MAD  at  baseline.
Individual  variables  Successful
(n  =  18)
Unsuccessful
(n  =  10)
p
Soft  palate  webbing  13  (72.2%)  7  (70%)  0.61
Posterior  soft  palate  6  (33.3%)  5  (50%)  0.32
Thick soft  palate  3  (16.7%)  1  (10%)  0.55
Thick uvula  13  (72.2%)  4  (40%)  0.10
Long uvula 11  (61.1%)  4  (40%)  0.25
Pharyngeal  alteration 12  (66.7%) 3  (30%) 0.07
MMI  class  III/IV 16  (88.9%) 10  (100%) 0.40
Grade  III/IV  palatine
tonsils
1 (5.5%) 0  (0.0%) 0.64
Class  II  dental  occlusion  2  (11.1%)  0  (0%)  0.40
Retrognathia  1  (5.5%)  2  (20%)  0.28
Ogival hard  palate  9  (50%)  4  (40%)  0.46
Craniofacial  alteration  11  (61.1%)  6  (60%)  0.66
Frequent  nasal
obstruction
10  (55.5%)  5  (50%)  0.54
Frequent  rhinopathy
complaint
10  (55.5%)  5  (50%)  0.54
Grade I  septal  deviation  8  (44.4%)  4  (40%)  0.57
Grade II/III  septal
deviation
1  (5.5%)  4  (40%)  0.04a
Inferior  nasal  turbinate
hypertrophy
7  (38.9%)  7  (70%)  0.12
Nasal alteration 7  (38.9) 8  (80%)  0.04a
MMI, modiﬁed Mallampati index; p, p-value (chi-squared test).
a
b
i
l
a
u
t
c
w
l
sNasal alteration 10  (58.8%)  5  (45.5%)  0.38
MMI, modiﬁed Mallampati index; p, p-value (chi-squared test).
lterations;  this  was  not  inﬂuenced  by  the  presence  of  other
bnormalities.  However,  there  was  no  inﬂuence  of  UA  and
acial  skeletal  alterations  on  treatment  adherence.
When  patients  were  assessed  for  adherence  before  and
fter  MAD  treatment,  it  was  observed  that  those  with  good
dherence  (60.7%),  according  to  the  criteria  used,  had  lower
alues  of  AHI  and  arousals  at  baseline,  suggesting  that
atients  in  this  group  had  a  milder  condition  than  those  in
he  poor  adherence  group.  Although  the  studies  are  contra-
ictory  when  stating  the  association  between  OSAS  severity
nd  adherence  to  MAD,13,14 it  is  known  that  MAD  is  more
ffective  in  patients  with  mild  OSAS,  in  whom  a  normal  AHI
an  be  reached  more  easily  and,  therefore,  where  the  dis-
ase  is  treated  in  a  more  satisfactory  way.  Thus,  in  this  group
f  patients  with  lower  AHI  values  and  less  sleep  fragmenta-
ion,  sleep  consolidation  was  probably  more  effective  and,
onsequently,  device  use  was  longer-lasting  and  may  have
ltered  the  adherence  in  a  positive  manner.
The  authors  did  not  observe  any  association  between
dherence  to  MAD  treatment  and  any  of  the  assessed
f
ﬁ
d
h
Table  7  Logistic  regression  of  factors  associated  with  successful  
B  p  E
Age  −0.298  0.02  0
NC −0.730  0.05  0
AHI pre  −0.285  0.05  0
NC, neck circumference; AHI, apnea/hypopnea index; OR, odds ratio; a Statistically signiﬁcant value.
natomical  UA  or  craniofacial  alterations  although  some
elieve  that  UA  alterations  as  a  result  of  MAD  use  could  result
n  some  degree  of  open-mouth  breathing  at  night  that  could
ead  to  difﬁculty  in  maintaining  lip  occlusion  during  sleep
nd  cause  the  patient  to  remove  it,  decreasing  the  device
se  and  adherence,  To  date,  there  have  been  no  studies  in
he  literature  that  made  a systematic  assessment  of  UAs  and
orrelated  these  data  with  MAD  treatment  adherence.
Adherence  to  MAD  has  been  assessed  in  other  studies,
hich  have  shown  that  adherence  does  not  depend  on  iso-
ated  factors,  but  on  a  number  of  them,  making  patients
uccessful  or  unsuccessful  users  of  MAD.  Marklund  et  al.
ound  that  24%  of  their  patients  stopped  using  MAD  in  the
rst  year  of  treatment,  and  there  was  no  association  with
isease  severity,  age,  gender,  nasal  obstruction,  or  smoking
abits.14
treatment  with  MAD.
xp  (B)  −  OR  95%  CI  for  Exp  (B)
Minimum  Maximum
.74  0.58  0.95
.48  0.23  1.00
.75  0.57  1.00
CI, conﬁdence interval.
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Almeida  et  al.  afﬁrmed  that  adherence  can  be  vari-
able  (ranging  from  4%  to  82%  in  studies),  depending  on
the  type  of  device  employed,  disease  severity,  and  possibly
patient  management.13 According  to  these  authors,  the  most
common  cause  for  treatment  discontinuation  was  patient
discomfort.  The  same  study  stated  that  most  existing  stud-
ies  assess  adherence  subjectively,  and  that  only  one  used  an
adherence  monitor,  which  indicated  a  mean  time  of  use  of
6.8  h  per  night.15
Adherence  was  evaluated  based  on  the  quantiﬁcation  of
the  time  of  MAD  use,  according  to  information  found  in
patients’  diaries.  Although  the  only  available  data  was  that
provided  by  the  patient’s  own  account,  who  could  omit  or
alter  the  information,  this  way  of  obtaining  information  was
the  closest  to  quantitative  data  concerning  adherence.
MAD  therapy  success  was  demonstrated  with  the  data
obtained  in  this  study  in  the  entire  group  and  after  analysis
of  adherence  and  success  groups,  as  there  was  a  signiﬁcant
reduction  in  AHI,  arousal  index  per  hour  of  sleep,  percent-
age  of  time  with  oxyhemoglobin  saturation  <90%,  and  the  ESS
score.  These  data  are  consistent  with  the  literature,  which
shows  several  studies  highlighting  these  ﬁndings  in  patients
with  mild  to  moderate  OSAS.2,13
The  success  rate  was  64.3%  according  to  the  criteria  we
used,  a  50%  reduction  in  baseline  AHI  associated  with  AHI  <10
events/h  with  the  implemented  treatment.  However,  even
in  the  group  considered  unsuccessful,  there  was  a  decrease
in  ESS  score,  AHI,  and  arousal  index,  as  well  as  improved
oxyhemoglobin  saturation.  Using  the  same  criteria,  a refer-
ence  was  found  in  the  literature  in  which  the  success  rate
was  46%.16
Other  authors  have  also  demonstrated  similar  rates
according  to  the  same  criteria.17,18 We  believe  the  wide
range  of  criteria  used  in  the  literature  to  characterize
MAD  treatment  success  is  a  major  limiting  factor  for  the
comparison  of  further  studies  with  what  has  already  been
published.  Currently,  there  is  a  tendency  to  consider  a  third
group,  that  of  patients  with  complete  response  to  treat-
ment,  characterized  by  a  reduction  in  AHI  <5  events/h.19
In  our  view  this  should  be  done  cautiously,  since  accord-
ing  to  current  diagnostic  criteria  for  OSAS,  an  individual
is  not  considered  as  having  this  syndrome  if  he  does  not
show  symptoms  of  snoring,  excessive  daytime  sleepiness,
and  witnessed  apnea,  even  if  the  AHI  is  between  5  and
15  events/h.7
Another  statistically  signiﬁcant  ﬁnding  was  the  younger
age  in  the  group  with  successful  treatment,  conﬁrmed  by
logistic  regression  as  one  of  the  predictors  for  the  success
of  the  MAD.  This  was  also  observed  by  Almeida  et  al.  and
Dal-Fabbro  et  al.9,13
Data  regarding  treatment  success  predictors  is  addressed
in  the  literature.  Otsuka  et  al.  observed  that  success  is
lower  in  patients  with  weight  gain  and  greater  anteropos-
terior  upper  airway  diameter.20 It  has  also  been  reported
that  younger  patients  with  positional  OSAS  (supine),  with
lower  baseline  AHI,  and  with  smaller  neck  circumference
have  a  higher  chance  of  success.13,21 Marklund  et  al.  also
reported  that  a  successful  outcome  with  positional  OSAS
is  more  common  in  men,  whereas  the  association  with
mild  apnea  is  more  prevalent  in  women.14 The  logistic
regression  observed  in  this  study  shows  that  reduced  neck
circumference  and  lower  basal  AHI,  in  addition  to  younger
C
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ge,  can  also  be  considered  successful  MAD  treatment
redictors.
Patients  were  considered  as  having  pharyngeal  alter-
tions  when  they  had  three  or  more  of  the  assessed
lterations.  This  was  based  on  the  study  by  Zonato  et  al.,
hich  showed  a  statistically  signiﬁcant  association  between
HI  and  the  presence  of  three  or  more  of  these  same
lterations.3 No  statistical  correlation  was  observed  with
espect  to  treatment  success  when  comparing  individuals
ho  had  these  alterations  with  those  who  did  not  have  them.
here  are  no  studies  in  the  literature  that  have  performed
his  type  of  correlation.
In  the  study  by  Marklund  et  al.,  the  authors  introduced
ew  evidence  in  relation  to  the  mechanism  of  action  of  MAD;
ccording  to  them,  nasal  patency  can  be  part  of  this  mech-
nism,  although  they  stated  that  more  studies  are  required
n  the  subject.  Also  in  the  same  study,  a  correlation  was
bserved  between  treatment  failure  and  nasal  obstruction,
nd  this  was  more  evident  in  women.  Nasal  obstruction
ssessment  was  performed  subjectively  in  that  study.14
Only  one  study  assessed  the  inﬂuence  of  nasal  resistance
n  the  treatment  of  OSAS  with  MAD,  in  38  patients  selected
or  this  treatment  modality.  Using  rhinomanometry,  Zeng
t  al.  showed  that  patients  considered  as  non-responders
ad  higher  nasal  resistance  in  the  sitting  position  than  the
esponders,  which  was  not  observed  when  the  same  analy-
is  was  performed  in  the  supine  position.  The  authors  also
bserved  an  increase  in  nasal  resistance  in  non-responding
atients  when  they  were  under  the  inﬂuence  of  MAD.6
In  spite  of  the  limitations  of  the  present  study  due
o  the  limited  number  of  patients  and  the  subjectivity
f  otorhinolaryngology  physical  examination,  a signiﬁcant
ssociation  was  observed  between  nasal  alterations  and
reatment  failure.  These  data  conﬁrm  assumptions  pre-
iously  raised  by  other  authors.  It  is  known  that  nasal
ermeability  increases  during  mandibular  advancement  in
ealthy  patients,  and  this  is  one  of  the  desired  mechanisms
f  action  with  this  device’s  use.22 Any  anatomical  alterations
n  this  pathway  (septal  deviation,  turbinate  hypertrophy,
asal  polyps)  may  interfere  with  the  success  of  the  applied
herapy.23
Nasal  obstruction  can  result  in  inadequate  lip  occlusion
uring  sleep.  Mouth  breathing  prevents  a  horizontal  force
rom  being  applied  to  the  jaw,  an  essential  factor  for  the
pplicability  of  mandibular  advancement,  that  limits  the
ptimum  performance  of  MAD.24
We  believe  that  nasal  obstruction  may  lead  to  an  increase
n  the  force  performed  during  inspiration,  which  promotes
pper  airway  collapse  and,  consequently,  decreased  efﬁ-
iency  of  MAD  in  these  patients.  This  hypothesis  has  been
aised  by  Zeng  et  al.,  and  the  ﬁndings  observed  in  this  study
urther  support  it.6 Thus,  we  believe  that  an  evaluation  of
As,  especially  of  nasal  obstructive  factors,  should  be  per-
ormed  with  caution  during  the  initial  evaluation  of  patients
ndergoing  treatment  for  OSAS  with  MAD,  as  possible  treat-
ents  of  nasal  alterations,  such  as  those  proposed  for  CPAP,
ay  be  adjuvants  for  the  successful  use  of  MAD.25onﬂicts of interest
he  authors  declare  no  conﬂicts  of  interest.
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